Testing Apatinib and Adebrelimab Plus GEMOX Chemotherapy for Advanced Unresectable Intrahepatic Cholangiocarcinoma in Adults

What this Trial Is About

Researchers are evaluating a new combination treatment for patients with advanced, unresectable intrahepatic cholangiocarcinoma ICC, a type of liver cancer. The study aims to assess the effectiveness and safety of using apatinib, an oral drug targeting VEGFR2, together with adebrelimab, an immune checkpoint inhibitor, plus GEMOX chemotherapy gemcitabine and oxaliplatin. This phase II trial seeks to improve tumor response rates beyond those typically seen with chemotherapy alone. Participants will receive adebrelimab intravenously at 1200 mg every three weeks and oral apatinib at 250 mg daily combined with up to six cycles of GEMOX chemotherapy every 21 days. The combination therapy will continue for up to two years or until the cancer worsens or side effects become unmanageable. The study explores whether specific biological markers can predict better treatment responses. During the trial, participants will be closely monitored for tumor response, side effects, progression-free survival, and overall survival. Researchers will collect data on adverse events from the first dose until 30 days after the last adebrelimab administration. The total participation may last up to two years, with multiple assessments, to thoroughly evaluate the treatments impact and safety.

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC